Mannatech, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022, compared with FY2021. This is an annual filing; it does not provide standalone fourth-quarter results. Mannatech sells nutritional supplements, skincare and weight-management products, primarily through network marketing, across the Americas, EMEA and Asia/Pacific. China operates through cross-border e-commerce. The company reports one segment.
Financial performance
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net sales | $137.2 million | $159.8 million |
| Gross profit / margin | $104.1 million / 75.9% | $125.6 million / 78.6% |
| Operating income (loss) / margin | $(0.4) million / (0.3)% | $9.0 million / 5.7% |
| Net income (loss) | $(4.5) million | $9.8 million |
| Basic and diluted EPS | $(2.35) | $4.95 basic; $4.71 diluted |
| Operating cash flow | $(2.6) million | $10.8 million |
| Cash and cash equivalents | $13.8 million | $24.2 million |
| Working capital | $5.1 million | $12.7 million |
- Sales fell 14.1% reported and 7.6% at constant currency. Unfavorable currency translation reduced reported sales by $10.5 million.
- Product sales declined 13.8% to $130.2 million; pack sales and associate fees fell 22.5% to $6.2 million. Average order value decreased to $175 from $190, and orders processed fell 5.6%.
- Sales declined in every region: Americas 11.1%, Asia/Pacific 14.2%, and EMEA 22.9%. The company attributed declines to fewer active associates/customers, lower order values and foreign exchange effects.
- Gross margin contracted 2.7 percentage points, primarily because of foreign exchange and higher supply-chain costs. Commissions and incentives were $55.5 million, or 40.4% of sales, versus $63.8 million, or 39.9%.
- The $4.0 million income tax provision despite a pretax loss reflects, among other factors, the Korean income-tax audit settlement and a larger valuation allowance on deferred tax assets. The reported effective tax rate was unusually negative at 837.4%.
Financial position and liquidity
- Cash, cash equivalents and restricted cash totaled $15.2 million at year-end, down $10.4 million from 2021. Operating activities used $2.6 million; investing used $1.1 million; financing used $4.3 million. Currency movements reduced cash by $2.4 million.
- Current assets were $35.0 million and current liabilities $29.8 million. Total liabilities were $35.0 million and shareholders’ equity was $14.2 million.
- The company reported no long-term debt instruments. Debt-like obligations included $0.3 million of notes payable, $0.1 million of finance lease liabilities and $5.8 million of operating lease liabilities.
- Financing cash use included $1.5 million in dividends, $2.0 million in share repurchases and $0.8 million in repayments of finance lease and other financing obligations. Dividends were lower than FY2021’s $4.3 million.
- Management said existing liquidity and operating cash flows should fund normal operations for the next 12 months, while noting that this depends on revenue and cost performance and that additional financing, if needed, may not be available on favorable terms.
Outlook, risks and unusual items
- No quantitative revenue or earnings guidance is provided. Management cited recruiting and retention, product introductions, market expansion, cost control and associate incentives as priorities.
- Active associate and preferred-customer positions declined to approximately 145,000 from 163,000. Five key products accounted for 50.2% of sales, creating product concentration risk; Ambrotose Life alone contributed 20.9%.
- Supply-chain exposure remains significant. Four suppliers accounted for 60.1% of cost of sales in 2022. A supply agreement requires $7.9 million of purchases through 2024; the company says it cannot currently identify alternative suppliers for Arabinogalactan and Manapol powder.
- In February 2023, the FDA refused entry to one lot of Ambrotose Life powder following testing; the company said it arranged return of the lot. A separate Ambrotose Life labeling issue was corrected. The filing describes the FDA testing as inconsistent with company and independent laboratory results.
- A new Korean customs audit, begun in February 2023, is reviewing origin determinations for certain imports from 2017–2021. Potential additional duties, VAT and penalties could not yet be estimated. The company also sought a Korean ruling on foreign-exchange reporting requirements for intercompany netting, which could lead to a penalty if reporting was required.
- The Busan customs valuation audit was resolved for $0.1 million, $0.4 million below the prior-year accrual. Other risks include foreign-exchange volatility, regulatory scrutiny of network marketing and product claims, COVID-related demand and supply disruptions, litigation, tax assessments, and compliance requirements across international markets.
- The company reported no legal reserve at year-end and said its financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to opine on internal control effectiveness.
Investor verification priorities
- Track whether sales, order values and active associate/customer counts stabilize, particularly in Asia/Pacific and EMEA.
- Confirm whether operating cash flow returns to positive territory and whether lower cash and working capital remain adequate for operations, dividends and commitments.
- Monitor the outcome and potential financial exposure of the 2023 Korean customs-origin audit and the Korean foreign-exchange reporting inquiry.
- Verify any further FDA action or product-supply impact related to the refused Ambrotose Life lot and corrected labeling.
- Assess the ability to meet the $7.9 million supplier commitment through 2024 and reduce dependence on concentrated suppliers and leading products.
- Review the assumptions supporting deferred tax asset realizability and the unusually large FY2022 tax provision.